Toronto - Delayed Quote CAD

Cardiol Therapeutics Inc. (CRDL.TO)

1.4700 -0.1500 (-9.26%)

At close: November 2 at 4:00:00 PM EST

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

CNW Group 3mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

CNW Group 4mo ago

CRDL.TO
-9.26%
CRDL
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Simply Wall St. 5mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

CNW Group 5mo ago

CRDL.TO
-9.26%
^IXIC

CRDL
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

PREMIUM
MT Newswires 6mo ago

CRDL.TO
-9.26%
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

PR Newswire 6mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

CNW Group 6mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise

MarketBeat 6mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

TMX Newsfile 6mo ago

CRDL.TO
-9.26%
CRDL
Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial

PREMIUM
MT Newswires 6mo ago

CRDL.TO
-9.26%
Cardiol Therapeutics Announces Year-End 2025 Update on Operations

TMX Newsfile 6mo ago

CRDL.TO
-9.26%
LLY
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

PR Newswire 1mo ago

CRDL

U.S. markets open in 2h 56m

Cardiol Therapeutics Inc. (CRDL.TO)

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders

Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy